Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

157
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
157
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

6
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
6
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

8
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
8
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

270
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
270
Retroviruses02:33

Retroviruses

12.7K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.7K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

220
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
220

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navepegritide: First Approval.

Drugs·2026
Same author

Pixavir Marboxil: First Approval.

Drugs·2026
Same author

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Correction: Donanemab: First Approval.

Drugs·2024
Same author

Donanemab: First Approval.

Drugs·2024
Same author

Sotatercept: First Approval.

Drugs·2024

Related Experiment Video

Updated: Oct 4, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.6K

Maribavir: First Approval.

Connie Kang1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 11, 2022
PubMed
Summary
This summary is machine-generated.

Maribavir is a new treatment for post-transplant cytomegalovirus (CMV) infections. It is approved for patients refractory to other therapies, marking a significant advancement in CMV treatment.

More Related Videos

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.2K
Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

3.5K

Related Experiment Videos

Last Updated: Oct 4, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.6K
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.2K
Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

3.5K

Area of Science:

  • Pharmacology and Virology
  • Infectious Diseases
  • Drug Development

Background:

  • Cytomegalovirus (CMV) infections pose a significant threat, particularly in post-transplant patients.
  • Existing therapies for CMV infections, including ganciclovir, valganciclovir, cidofovir, and foscarnet, have limitations, especially in cases of refractory disease or genotypic resistance.
  • The pUL97 kinase is a key viral enzyme targeted in CMV treatment strategies.

Purpose of the Study:

  • To summarize the key milestones in the development of maribavir, a pUL97 kinase inhibitor.
  • To highlight the regulatory pathway and approval of maribavir for CMV infections.
  • To provide an overview of maribavir's role in treating refractory post-transplant CMV infections.

Main Methods:

  • Review of preclinical and clinical development data for maribavir.
  • Analysis of regulatory submissions and approval processes.
  • Summary of clinical trial outcomes for maribavir in CMV infections.

Main Results:

  • Maribavir, a selective inhibitor of the CMV pUL97 kinase, has demonstrated efficacy in treating CMV infections.
  • The drug received US approval for post-transplant CMV infection/disease refractory to other treatments.
  • Approval includes adult and pediatric patients (≥ 12 years, ≥ 35 kg) with or without genotypic resistance.

Conclusions:

  • Maribavir represents a significant therapeutic advancement for patients with refractory post-transplant CMV infections.
  • The development and approval of maribavir offer a new, targeted treatment option for a challenging clinical scenario.
  • This milestone underscores the importance of developing novel agents against critical viral targets like pUL97.